Cytek Biosciences, Inc. (CTKB)

Market Cap	940.71M
Revenue (ttm)	183.12M
Net Income (ttm)	-14.12M
Shares Out	135.55M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	48.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,630,948
Open	6.90
Previous Close	6.86
Day's Range	6.76 - 7.08
52-Week Range	3.80 - 13.77
Beta	0.66
Analysts	Buy
Price Target	9.67 (+39.34%)
Earnings Date	Nov 7, 2023

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The comp...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 688
• Stock Exchange: NASDAQ
• Ticker Symbol: CTKB

Financial Performance

In 2022, CTKB's revenue was $164.04 million, an increase of 28.20% compared to the previous year's $127.95 million. Earnings were $2.58 million, a decrease of -14.16%.

Analyst Forecast

According to 4 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is $9.67, which is an increase of 39.34% from the latest price.

Price Target

$9.67

(39.34% upside)

Analyst Consensus: Buy